17alpha-estradiol

A Phase 1 report describes an oral sulfate formulation, while much of the aging interest comes from mice. The accessible abstract does not establish human aging benefit.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: Mouse lifespan findings or an early safety report establish safe human longevity use.

What the reviewed records say:

The gap: Full clinical details of the Phase 1 report were not accessible. Dose, exposure, adverse events and human aging efficacy remain unresolved.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

Full clinical details of the Phase 1 report were not accessible. Dose, exposure, adverse events and human aging efficacy remain unresolved.